Extended Data Figure 3 : YAP/TAZ are stabilized in shLATS cells but do not impose their canonical signature.

From: The Hippo kinases LATS1 and 2 control human breast cell fate via crosstalk with ERα

Extended Data Figure 3

a, YAP/TAZ signalling increases upon removal of LATS. Immunoblots (left) and qPCR analysis (right) of shNT- and shLATS-treated PHBECs. Data are mean ± s.d. (n = 6 experimental replicates), *P < 0.05. b, GSEA analysis of the shLATS profiles with datasets in which YAP was overexpressed (left and middle) or with a YAP/TAZ gene set derived from http://www.reactome.org/ (right). Left, NES = 0.84; FDR = 0.726; P = 0.726. Middle, NES = 0.91; FDR = 0.58; P = 0.58. Right, NES = 0.1.17; FDR = 0.251; P = 0.251. There was no enrichment of the shLATS-treated PHBEC profile with the published YAP- or YAP/TAZ-driven gene set.